Cantor Fitzgerald Maintains a Buy Rating on Neos Therapeutics (NEOS)


Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Neos Therapeutics (NEOS) today and set a price target of $20. The company’s shares opened today at $2.38, close to its 52-week low of $1.40.

Chen commented:

“. Post a solid quarter of execution in 4Q18, we reiterate our OW rating and 12-month PT of $20 for NEOS shares. The peak sales potential of NEOS’s ADHD platform and pipeline are underappreciated, in our view. We think continued success with the sales of its key drugs (Adzenys XR-ODT, Cotempla XR- ODT and Adzenys ER) as well as pipeline advancements (NT-0400 and NT-0502) will drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 41.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neos Therapeutics with a $20 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.25 and a one-year low of $1.40. Currently, Neos Therapeutics has an average volume of 339.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30,1994 and is headquartered in Grand Prairie, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts